SCHEMBL8202269

SCHEMBL8202269

Clc1ccc2c(c1)C=Nc1ccccc1N2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.42
CHRM1 P11229 4/20 0.42
DRD4 P21917 2/20 0.42
DRD3 P35462 2/20 0.42
CHEK1 O14757 1/20 0.41
DRD1 P21728 8/20 0.40
CHRM3 P20309 3/20 0.40
KCNH2 Q12809 3/20 0.40
BCHE P06276 2/20 0.40
ACHE P22303 2/20 0.40
CYP1A2 P05177 2/20 0.40
CHRM2 P08172 2/20 0.40
CHRM4 P08173 2/20 0.40
CYP3A4 P08684 2/20 0.40
CHRM5 P08912 2/20 0.40
CYP2D6 P10635 2/20 0.40
NOX1 Q9Y5S8 1/20 0.40
MTOR P42345 1/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521082 0.87 DRD2 (0.43) DRD2CHRM1DRD4DRD3CHEK1
SCHEMBL8203995 0.87 BCHE (0.44) DRD2CHRM1DRD4DRD3CHEK1
SCHEMBL20067134 0.83 ROS1 (0.42) DRD2CHRM1DRD1NOX1MEN1
SCHEMBL20067128 0.80 NOX1 (0.44) DRD2CHRM1DRD1NOX1MEN1
SCHEMBL8204505 0.80 TP53 (0.33) DRD4CHEK1BCHEACHECYP1A2
SCHEMBL5138230 0.80 TRPA1 (0.47) CHRM1CHEK1CYP1A2MEN1KMT2A
SCHEMBL309794 0.80 MAPT (0.50) MEN1KMT2AMAPTSMN1; SMN2HSD17B10
SCHEMBL8204796 0.76 CYBB (0.44) CHRM1NOX1MEN1KMT2AMAPT
SCHEMBL8206931 0.76 TRPA1 (0.51) CHRM1CYP1A2CYP2D6NOX1MEN1
SCHEMBL20067130 0.73 CSNK1G1 (0.41) DRD2DRD1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6103715-A COMPOUNDS THAT BIND TO THE DOPAMINE D4 RECEPTOR AND THEIR USE AS ANXIOLYTIC AGENTS, TREATMENT FOR SCHIZOPHRENIA, AND DRUG SCREENING; SIDE EFFECT REDUCTIOON ALLELIX BIOPHARMACEUTICALS INC. (CA) 2000-08-15 US disclosed
US-5538965-A TREATMENT OF PSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA AND ANXIETY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1996-07-23 US disclosed